Search research articles
Contact Us
Filters
Showing results (211-220 of 231) with videos related to
Page
of 24
Sort By:
The Lancet. Oncology
|
August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
Blood
|
April 17, 2020
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Catarina Maia, Noemi Puig, Maria-Teresa Cedena, et al.
The Lancet. Oncology
|
May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Haematologica
|
September 22, 2018
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.
Blood Cancer Discovery
|
July 11, 2025
Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Mireia Uribe-Herranz, Aina Oliver-Caldés, Neus Martínez-Micaelo, et al.
Blood
|
June 16, 2021
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Daniel Alameda, Ibai Goicoechea, Marco Vicari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2019
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Bruno Paiva, Noemi Puig, Maria-Teresa Cedena, et al.
Blood
|
June 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
Juan-Jose Lahuerta, Jesús F San-Miguel, Ana Jiménez-Ubieto, et al.
Nature Medicine
|
April 20, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Omar Nadeem, David M Cordas Dos Santos, Sarah Nikiforow, et al.
The New England Journal of Medicine
|
December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Luciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
Page
of 24
Search research articles
Search
Showing results (211-220 of 231) with videos related to
Sort By:
Page
of 24
The Lancet. Oncology
|
August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
Blood
|
April 17, 2020
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Catarina Maia, Noemi Puig, Maria-Teresa Cedena, et al.
The Lancet. Oncology
|
May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Haematologica
|
September 22, 2018
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.
Blood Cancer Discovery
|
July 11, 2025
Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Mireia Uribe-Herranz, Aina Oliver-Caldés, Neus Martínez-Micaelo, et al.
Blood
|
June 16, 2021
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Daniel Alameda, Ibai Goicoechea, Marco Vicari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2019
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Bruno Paiva, Noemi Puig, Maria-Teresa Cedena, et al.
Blood
|
June 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
Juan-Jose Lahuerta, Jesús F San-Miguel, Ana Jiménez-Ubieto, et al.
Nature Medicine
|
April 20, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Omar Nadeem, David M Cordas Dos Santos, Sarah Nikiforow, et al.
The New England Journal of Medicine
|
December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Luciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
Page
of 24